SYMATESE enters the U.S. dermal fillers market.
SYMATESE is pleased to announce that Evolus Inc., California, will launch in the U.S. on Friday, April 18th the Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, next-generation hyaluronic acid injectable gels powered by cutting-edge COLD-X™ TECHNOLOGY developed by SYMATESE, designed for long-lasting and natural-looking results. This milestone marks SYMATESE’s bold entry into the $1.6 billion U.S. dermal filler market and accelerates its global expansion, with upcoming launches in Europe, China, and Brazil.
Please view the US announcement made by Jean-Paul Gerardin & David Moatazedi, respective CEOs of SYMATESE & Evolus
For more information on the Evolysse™ US launch refer to Evolus Press release
